Published January 22, 2018
RNAi technology is a process which inhibits gene expression by neutralising the targeted mRNA. In the fields of pharmaceutical and biotechnology, RNAi technology will help to improve technologies in therapeutics and drug discovery. RNAi is commonly known as co-suppression or quelling.
Europe RNAi Technology Market Segments Size & Growth:
Europe RNAi Technology Market is accounted for $XX billion in 2017 and expected to grow at a CAGR of XX% to reach $XX billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth by increasing research activities in RNAi technology mainly in cancer. However, reimbursement and FDA regulations hinder the growth of the Europe RNAi technology market.
Europe RNAi Technology Market Segments Share:
Europe RNAi Technology Market is categorised into by application which consists of agriculture, drug discovery, research & development, and therapeutics. Within the RNAi technology market, the therapeutic segment is further classified by oncology, heart ailment, neurodegenerative disease, respiratory disorders, autoimmune hepatitis, and metabolic disorders. Research and development have the most significant share due to increase in research developments in RNAi technology mainly on chronic diseases, such as cancer.
By Geography, Germany is dominating the Europe RNAi technology market, and the growth in Europe is mainly attributed because of considerable investments in R&D activities and advancements in therapies. Furthermore, UK is witnessing the fastest growth during the forecast period, due to rapidly increasing pharmaceutical infrastructure and the government initiatives.
Europe RNAi Technology Market Segments Trends:
Europe RNAi Technology Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.4 SWOT Analysis
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1.1 Increasing research activities in RNAi technology mainly in cancer
4.2.1 FDA regulations and reimbursement facilities
4.3.1 Rising demand for genetics-based on In-Vitro-Diagnostics
4.4.1 Determining design for siRNA sequence and off-target effects.
Chapter 5 Europe RNAi Technology Market – By Application
5.2 Research and development
5.3 Drug discovery
5.4.1 Autoimmune Hepatitis
5.4.2 Ocular Disorders
5.4.3 Hepatitis B and C
5.4.5 Respiratory Disorders
5.4.6 Heart ailments
5.4.7 Neurodegenerative disease
Chapter 6 Europe RNAi Technology Market – By Geography
6.2.6. Rest of Europe
Chapter 7 Europe RNAi Technology Market – Company Profiles
7.1. Ionis Pharmaceuticals Inc.
7.2. Benitec Biopharma Ltd
7.3. Silence Therapeutics
7.4. Takara Bio Inc. (Clonetch)
7.5. Quark Pharmaceuticals Inc.
7.6. Thermo Fisher Scientific Inc.
7.7. F. Hoffmann-La Roche Ag (Roche)
7.8. Alnylam Pharmaceuticals
7.9. Pfizer Inc.
7.11 Merck & Co. Inc. (Sigma Aldrich)
7.12 Qiagen NV
7.13 Arcturus Therapeutics
Chapter 8 Europe RNAi Technology Market – Competitive Landscape
8.1 Market Share Analysis
8.2 Strategies Adopted by top companies
8.3 Mergers, Acquisitions, Collaborations & Agreements
Chapter 9 Market Insights
9.1. Industry Experts Insights
9.2. Analysts Opinions
9.3. Investment Opportunities
Chapter 10 Appendix
10.1 List of Tables
10.2 List of Figures